Highbridge Capital Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Highbridge Capital Management’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-2,327	Closed	-$466K	–	1942
2015 Q4	$466K	Buy	+2,327	New	+$464K	0.01%	1024
2015 Q3	–	Sell	-427	Closed	-$404K	–	1922
2015 Q2	$404K	Buy	+427	New	+$349K	0.01%	1042
2015 Q1	–	Sell	-586	Closed	-$440K	–	1670
2014 Q4	$465K	Buy	+586	New	+$315K	0.01%	843

Other funds holding TTPH

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Highbridge Capital Management's TTPH Position: Q1 2016 in Review

Highbridge Capital Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2016, closing a stake of 2,327 shares — an estimated $466K sold.

Highbridge Capital Management first reported a position in TTPH in Q4 2014 and held it in 3 quarters. The position peaked at $466K in Q4 2015. 101 funds tracked by Wall St. Rank hold TTPH as of Q1 2016.

Highbridge Capital Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
Highbridge Capital Management sold 2,327 Tetraphase Pharmaceuticals, Inc. shares in Q1 2016, an estimated $466K.
Highbridge Capital Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2014 and held it in 3 quarters.
Highbridge Capital Management's Tetraphase Pharmaceuticals, Inc. position peaked at $466K in Q4 2015.
101 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2016.

Based on Highbridge Capital Management's 13F filing for Q1 2016, filed 16 May 2016.